Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium-90 DOTA-biotin-avidin
- Development stage
- Preclinical
- Lead developer
- University of California, Davis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravesical
01
Overview
yttrium-90 DOTA-biotin-avidin ([90Y]DBA) is an experimental radiopharmaceutical developed for the intravesical treatment of non-muscle invasive bladder cancer (NMIBC). It consists of the high-energy beta-emitting radioisotope yttrium-90 chelated by DOTA and conjugated to a biotin-avidin complex. The mechanism of action involves the delivery of localized, short-range beta radiation directly to the bladder urothelium to induce DNA damage and cell death in malignant tissues. A critical design feature of the DBA complex is its high molecular weight, which prevents systemic absorption through the bladder wall into the bloodstream. This localization maximizes the therapeutic effect on superficial tumors while minimizing systemic toxicity and preserving the integrity of the underlying bladder histology. Preclinical studies in orthotopic murine models have demonstrated significant antitumor activity and a favorable safety profile.
- Other names
- yttrium-90 DOTA-avidin-biotinyttrium90 DOTA-avidin-biotinyttrium 90 DOTA-avidin-biotin90Y-DOTA-biotin-avidin[90Y]DOTA-biotin-avidin
02
Targets
AVD (Avidin)
Beyond the preview
Go deeper on yttrium-90 DOTA-biotin-avidin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium-90 DOTA-biotin-avidin.